Tamoxifen (TAM), a selective oestrogen receptor modulator, is one of the most used treatments in oestrogen receptor-positive (ER+) early and metastatic breast cancer (BC) patients. The response to TAM has a high degree of inter-individual variability. This is mainly due to genetic variants in CYP2D6 gene, as well as other genes encoding proteins involved in the TAM pharmacokinetic and/or pharmacodynamic. Therefore, prediction of the TAM response using these genetic factors together with other non-genetic variables may be relevant to improve breast cancer treatment. Thus, in this work, we used genetic polymorphisms and clinical variables for TAM response modelling. One hundred sixty-two ER+ BC patients with 2 years of TAM treatment were retrospectively recruited, and the genetic polymorphisms CYP2D6*4, CYP3A4*1B (CYP3A4*1.001), CYP3A5*3, UGT2B7*2, UGT2B15*2, SULT1A1*2, and ESRA V364E were analyzed by PCR-RFLP. Concomitantly, the therapeutic response was obtained from clinical records for association with genotypes using univariate and multivariate biostatistical models. Our results show that UGT2B15*1/*2 genotype protects against relapse (OR = 0.09; p = 0.02), CYP3A5*3/*3 genotype avoids endometrial hyperplasia (OR = 0.07; p = 0.01), SULT1A1*1/*2 genotype avoids vaginal bleeding (OR = 0.09; p = 0.03) and ESRA V364E/364E genotype increases the probability of vaginal bleeding (OR = 5.68; p = 0.02). Logistic regression models, including genomic and non-genomic variables, allowed us to obtain preliminary predictive models to explain relapse (p = 0.010), endometrial hyperplasia (p = 0.002) and vaginal bleeding (p = 0.014). Our results suggest that the response to TAM treatment in ER + BC patients might be associated with the presence of the studied genetic variants in UGT2B15, CYP3A5, SULT1A1 and ESRA genes. After clinical validation protocols, these models might be used to help to predict a percentage of BC relapse and adverse reactions, improving the individual response to TAM-based treatment.

Keywords: breast cancer, pharmacokinetics, pharmacodynamics, polymorphism, ADR, Relapse
1 INTRODUCTION

Breast cancer (BC) is the second leading cause of cancer death in women (American Cancer Society, 2017) and is caused by many factors, such as age, breast density, heredity, and exposure to oestrogens (Kumar et al., 2010). Breast cancer (BC) patients with oestrogen receptor positivity (ER+) are treated in addition to surgery, chemotherapy, and/or radiation therapy with hormone therapy (Maughan et al., 2010; McDonnell and Wardell 2010; NCI 2012). Tamoxifen (TAM), a type of hormonal therapy known as a selective oestrogen receptor modulator, behaves as an oestrogen antagonist in the breast and as an agonist in the endometrium (Lewis and Jordan 2005; Terán and Teppa 2005; Hertz et al., 2009; NCI 2012), and despite the new hormonal agents, TAM remains the drug of choice for any BC stage (Davies et al., 2011) since it increases the disease-free time in pre- or postmenopausal women, reducing the annual death rate by 34% (MINSAL, 2005; Untch and Thomssen, 2010). However, the response among patients is variable in terms of efficacy and side effects.

TAM undergoes extensive biotransformation in the liver by phase I (CYP) and phase II enzymes. Phase I generates, among other metabolites, N-desmethyltamoxifen (N-desmethylTAM), 4-hydroxy tamoxifen (4-hydroxyTAM), and 4-hydroxy-N-desmethyltamoxifen (endoxifen) (Brauch et al., 2009). Endoxifen and 4-hydroxyTAM are the main and unique active metabolites of TAM due to their high affinity to ERs and their activity being 30- to 100-fold greater than TAM itself (Wakeling and Slater 1980; Johnson et al., 2004; Fernández-Santander et al., 2007; Brauch et al., 2009). In vitro studies have determined that these metabolites are more effective in reducing cell proliferation (Jordan et al., 1977; Clarke et al., 2003; Borges et al., 2006). The two most abundant metabolites in plasma are N-desmethylTAM and endoxifen (Clarke et al., 2003). Subsequently, these metabolites undergo biotransformation by phase II enzymes, the main enzymes involved being SULT1A1, UGT2B7, and UGT2B15 (Nishiyama et al., 2002). TAM has a long half-life, and steady-state concentrations are obtained at 4 weeks for TAM and at 8 weeks for N-desmethylTAM (Buckley and Goa, 1989; Lien et al., 1992; Kisanga et al., 2004).

Differences have been found between the response to TAM and the histological type, degree of differentiation of the breast tumor cells, age, and state of menopause in the patient. TAM has an overall response rate of almost 75% in patients with ER+ and PR+ BC. In the case of adjuvant treatment, TAM reduces the risk of relapse by 25% and mortality by 17% (Fisher et al., 1998; Davies et al., 2011). On the other hand, the long-term safety of TAM is well elucidated, and possible harmful effects on bone metabolism, endometrial cancer, thromboembolic diseases, and cognitive disorders due to chronic oestrogen deprivation in brain tissue have been described (Fisher et al., 1998; Cuzick et al., 2002; Cuzick, 2005). A 1% increase in the incidence of endometrial cancer has been observed due to its oestrogen-inducing effect in the uterus and thromboembolic events in 1–2% of cases.

Despite several studies having been conducted, after 3 decades, there are still differences in the TAM response that have not been explained. It is known that these variations in the response to drugs are multifactorial, the result of the interaction between multiple and complex genetic, physiological and environmental factors (Ma and Lu 2011). A potential explanation is the presence of genetic variants in the genes encoding biotransformation enzymes affecting their efficacy and safety (Zhou et al., 2008). In this respect, undoubtedly genetic variation in the CYP2D6 driving to ultrarapid (XX), intermediate metabolizer or poor metabolizer phenotypes (e.g. *3, *4, *5, *9, *10, *17 haplotypes) may affects plasma concentrations of TAM and its metabolites, as CPIC has established in the updated guidelines (Goetz et al., 2018). CYP2D6*4 (rs3892097) is associated with decreased side effects, such as hot flashes, disease-free time, and survival rate (Goetz et al., 2005; Jin et al., 2005; Schroth et al., 2007; Bijl et al., 2009; Ramón y Cajal et al., 2010; Rae et al., 2012), and decreased serum levels of TAM metabolites (Gjerde et al., 2007; Kiyotani et al., 2010; Lim et al., 2011; Madlensky et al., 2011). In addition, CYP3A4*1B (currently named CYP3A4*1.001, rs2740574) is associated with a 3-fold higher risk of endometrial cancer in TAM-treated BC patients (Chu et al., 2007). CYP3A5*3 (rs776746) is associated with characteristics of the tumor in BC postmenopausal women treated with TAM (Tucker et al., 2005). On the other hand, CYP2C9 *2 and *3 variants reduce the concentration of TAM metabolites, affecting the therapeutic response (Mürdter et al., 2011).

Phase II enzymes also affect TAM response. SULT1A1*2 (rs9282861) increases the risk of relapse in TAM-treated BC patients (Wegman et al., 2005). UGT2B15*2 (rs1902023) decreases the risk of relapse of BC (Nowell et al., 2005). Furthermore, the presence of UGT2B15*2 and SULT1A1*2 is associated with a lower risk of relapse and a significant reduction in survival time in patients with BC treated with TAM (Nowell et al., 2005).

Finally, several mutations have been identified in the oestrogen receptor alpha gene (ESRA) in BC patients (Herynk et al., 2004); however, their effect on the efficacy and safety of TAM treatment has not been elucidated. In this respect, using SIFT and PolyPhen bioinformatic tools, it was established that the single nucleotide polymorphism (SNP) ESRA (OMIM* 133430) V364E (rs121913044; 1453T>A; Val364Glu) generates a deleterious change with possible damage to the N-terminus of the hormone-binding domain in the ER, giving rise to a 40 times lower affinity for oestrogen (Flicek et al., 2011). This SNP also exhibits a dependence on oestrogen for binding to an ERE, although it maintains its negative dominant activity entirely. Therefore, ESRA V364E is highly active and capable of repressing ER-mediated transcription, both when ESRA V364E and normal ESRA proteins are present together in cells and even without DNA binding (Wrenn and Katzenellenbogen 1993; Ince et al., 1995; McInerney et al., 1996).

Although in the last decade several studies have investigated genetic variants in TAM-metabolizing enzymes that might determine the differences in the response to treatment in patients with BC, there are still controversies about their relationship with the response (Brauch and Schwab, 2014; Brewer et al., 2014; Province et al., 2014; Binkhorst et al., 2015). To address this question, we aimed to study the association among response (relapse and ADR) and 7 genetic
variants in genes encoding proteins involved in the pharmacokinetics and pharmacodynamics of TAM (CYP2D6*4, CYP3A4*1B (CYP3A4*1.001), CYP3A5*3, SULT1A1*2, UGT2B7*2, UGT2B15*2 and ESRA V364E) in women with hormone-dependent BC and under adjuvant treatment with TAM. The main goal is to generate predictive models to approximate the response of patients according to their genetic-metabolic characteristics.

2 PATIENTS AND METHODS

2.1 Study Design

A retrospective case-control study was carried out from January 2014 to January 2015 at the Polyclinic of Oncology of the National Institute of Cancer (INC). The sample size was determined according to the frequency of carriers with the variant allele carriers in the population under study, using PS Power and Sample Size Calculations Version 3.0, January 2009, considering an 80% power; α = 0.05; OR = 2.0; and the less frequent CYP3A4*1B (CYP3A4*1.001, rs2740574), according to the literature (Puentes and Silveyra, 2019).

2.2 Patients

One hundred sixty-two (162) patients were enrolled. The inclusion criteria were as follows: 1) patients with histologically confirmed BC, 2) in adjuvant treatment with 20 mg of tamoxifen (Novadex®) daily for at least 24 months; 2) > 18 years-old, 3) positive ER and negative HER-2 status, 4) negative PR, triple-negative or Her-2 positive patients; 3) concomitant treatments with vitamin K antagonists (warfarin, acenocoumarol or dicoumarol), serotonin reuptake antagonist antidepressants (fluoxetine or paroxetine), mitomycin, nitonavir, primidone, or chemotherapy (florouracil, methotrexate or cyclophosphamide), 4) chronic unbalanced systemic pathology or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatment or other active cancers and, 5) aromatase inhibitor treatme
### TABLE 1 | Characteristics of patients (n = 162).

| Variables                                      | N*   | (%)      | x ± SD  |
|------------------------------------------------|------|----------|---------|
| **Anthropometric characteristics**            |      |          |         |
| Age (years)                                    | 160  | (98.77)  | 58 ± 13 |
| Weight, (Kg)                                   | 160  | (98.77)  | 69 ± 15 |
| Height, (m)                                    | 156  | (96.30)  | 1.55 ± 0.06 |
| BMI (Kg/m²)                                    | 156  | (96.30)  | 29 ± 6  |
| **Socio-genetic gradient**                     |      |          |         |
| Blood type                                     |      |          |         |
| AB                                             | 3    | (1.85)   |         |
| A                                              | 21   | (12.96)  |         |
| B                                              | 8    | (4.94)   |         |
| O                                              | 66   | (40.74)  |         |
| N.D.                                           | 64   | (39.51)  |         |
| Number of members in the family                |      |          | 3 ± 2   |
| **Socioeconomic (income/member)**              |      |          |         |
| <$CLP135,000 (US 200)                          | 33   | (21.15)  |         |
| $CLP135,001–500,000 (US 200–750)               | 91   | (58.33)  |         |
| $CLP 500,001–1,000,000 (US >750–1,450)         | 27   | (17.31)  |         |
| >$CLP 2,000,000 (US >2,900)                    | 5    | (3.21)   |         |
| N.D.                                           | 6    | (3.85)   |         |
| **Risk factor’s**                              |      |          |         |
| Alcoholic Habit Presence                       | 0    | (100)    |         |
| Presence of Smoking Habit                      | 48   | (30.19)  |         |
| Presence family history of some cancer         | 100  | (62.89)  |         |
| Presence Family History of breast or ovary cancer | 43  | (27.04)  |         |
| **Gynecological Characteristics**              |      |          |         |
| Menarche age (years)                           | 153  | (94.44)  | 13 ± 2  |
| Number of Gestations                           | 160  | (98.77)  | 3 ± 2   |
| Number of deliveries                           | 160  | (98.77)  | 3 ± 2   |
| Number of Abortions                            | 160  | (98.77)  | 1 ± 1   |
| Breastfeeding time (months)                    | 137  | (84.57)  | 24 ± 28 |
| Oral Contraceptive Treatment (months)          | 154  | (95.06)  | 39 ± 69 |
| Menopausal status                              | 68   | (41.98)  |         |
| **Premenopause**                               |      |          |         |
| Postmenopause                                  | 94   | (58.02)  |         |
| **Treatment with HRT (months)**                | 21   | (22.34)  | 11 ± 46 |
| **Pathological Features**                      |      |          |         |
| Age of diagnosis (years)                       | 160  | (98.77)  | 54 ± 13 |
| Cancer stage at diagnosis                      | 59   | (36.42)  |         |
| II                                             | 83   | (51.23)  |         |
| III                                            | 20   | (12.35)  |         |
| Tumor Histology                                |      |          |         |
| In situ Ductal carcinoma (DCis)                | 4    | (2.47)   |         |
| Invasive Ductal Carcinoma (IDC)                | 139  | (85.80)  |         |
| Invasive Lobular Carcinoma (ILC)               | 8    | (4.94)   |         |
| Others, (IBC, IPC, etc.)                      | 9    | (5.68)   |         |
| N.D.                                           | 2    | (1.23)   |         |
| Cell Differentiation Degree                    |      |          |         |
| G1                                             | 41   | (25.31)  |         |
| G2                                             | 78   | (48.15)  |         |
| G3                                             | 25   | (15.43)  |         |
| N.D.                                           | 18   | (11.11)  |         |
| **Treatment before TAM**                       |      |          |         |
| Surgery                                        | 12   | (7.41)   |         |
| Surgery + radiotherapy                         | 37   | (22.84)  |         |
| Surgery + chemotherapy                         | 13   | (8.02)   |         |
| Surgery + chemotherapy + radiotherapy          | 36   | (22.22)  |         |
| No treatment                                   | 64   | (39.51)  |         |

N.D: no data; TAM: tamoxifen; SD: standard deviation; IBC: inflammatory breast cancer; IPC: intracystic papillary carcinoma; HRT: hormone replacement therapy.

*Some data for patients were lost from the clinical files, so the numbers are lower than the total.*
The polymorphisms were evaluated using co-dominant (wild type vs heterozygote vs variant), dominant (wild type vs heterozygote/variant), and recessive (wild type/heterozygote vs variant) inheritance models. Bi-variable analyses were performed to determine the association between the events (relapses and ADR), considered the dependent variables, and the characteristics of the patients, considered the independent variables. Thus, the independent variables considered were BMI, blood group, smoking habit, socioeconomic status, treatment with oral contraceptives, hormone replacement therapies, age at menarche, menopausal status, family history of cancer, age at diagnosis, cancer stage, and presence of genetic variants (exposure variable).

Multivariate logistic regression models and multivariate linear regression analyses were employed to investigate associations between genetic or non-genetic characteristics and relapse or ADR. The logistic multivariate models were adjusted stepwise using a forward and backward procedure to include potentially relevant variables to derive statistical association models characterized by pseudo R². All association studies were assayed by choosing parameters with a better statistical association for each analysis. The odds ratio (OR), or coefficients (Coef.), and 95% confidence intervals (CIs) are reported in the multivariate logistic regression models.

### 2.5 Ethics

The study was carried out under strict ethical procedures recommended by the Ethics Committee of the Faculty of Medicine of the University of Chile (July 24, 2013) and the

---

**TABLE 2 | Relapse and Adverse drug reactions (ADRs) in patients.**

| Clinical response | N  | (%) |
|-------------------|----|-----|
| Relapse           |    |     |
| No                | 148| (91.36) |
| Yes               | 9  | (5.56) |
| N.D.              | 5  | (3.09) |
| ADRs              |    |     |
| Endometrial cancer|    |     |
| No                | 161| (99.38) |
| Yes               | 1  | (0.62) |
| Endometrial hyperplasia |    |     |
| No                | 147| (90.74) |
| Yes               | 15 | (9.26) |
| Vaginal bleeding  |    |     |
| No                | 154| (96.06) |
| Yes               | 8  | (4.94) |
| Phlebitis         |    |     |
| No                | 160| (96.77) |
| Yes               | 2  | (1.23) |
| Headache          |    |     |
| No                | 157| (96.91) |
| Yes               | 5  | (3.09) |
| Nausea            |    |     |
| No                | 156| (96.30) |
| Yes               | 6  | (3.70) |
| Hot flush         |    |     |
| No                | 62 | (38.27) |
| Yes               | 100| (61.73) |
| Cramps            |    |     |
| No                | 142| (87.65) |
| Yes               | 20 | (12.35) |
| Bone pain         |    |     |
| No                | 140| (86.42) |
| Yes               | 22 | (13.58) |
| Urticaria         |    |     |
| No                | 158| (97.53) |
| Yes               | 4  | (2.47) |

ADR, adverse drug reaction, evaluated with Common Terminology Criteria for Adverse Events [CTCAE], 2010. N.D: No data. Control groups include patients who do not present the analyzed ADRs (relapse, hot flashes, etc., i.e. “No”), and Cases groups include patients who have the ADRs (i.e. “Yes”).

---

**TABLE 3 | Genotype and allele frequencies of the studied polymorphisms in patients.**

| Polymorphisms | N | Frequency |
|---------------|---|-----------|
| CYP2D6        |   |           |
| *1/*1 (GG)    | 121 | 0.747 |
| *1/*4 (GA)    | 37  | (0.228) |
| *1/*4 (AA)    | 4   | (0.025) |
| *4 (A)        | 279 | (0.861) |
| *4 (A)        | 45  | (0.139) |
| CYP3A4        |   |           |
| *1/*1 (AA)    | 144 | (0.689) |
| *1/*1B (AG)   | 17  | (0.105) |
| *1B/*1B (GG)  | 1   | (0.006) |
| *1 (A)        | 305 | (0.941) |
| *1B (A)       | 19  | (0.059) |
| CYP3A5        |   |           |
| *1/*1 (AA)    | 5   | (0.031) |
| *1/*3 (AG)    | 59  | (0.364) |
| *3/*3 (GG)    | 98  | (0.605) |
| *1 (A)        | 69  | (0.213) |
| *3 (G)        | 255 | (0.787) |

---

**TABLE 4 | Estrogen receptor. TAM therapeutic target**

| ESRA          | N  | Frequency |
|---------------|----|-----------|
| V364E         | 101| (0.623) |
| 364V/364V (TT)| 33 | (0.204) |
| 364V/364V (TA)| 88 | (0.543) |
| 364V/364V (TC)| 41 | (0.253) |
| 364V/364V (CT)| 72 | (0.444) |
| 364V/364V (CC)| 71 | (0.438) |
| 364V (T)      | 110| (0.340) |
| 364V (C)      | 214| (0.660) |

TAM: tamoxifen; CYP: Cytochrome P450; SULT: sulfotransferase; UGT: Uridine 5'-diphospho-Glucuronosyltransferase, ESR: estrogen receptor. *CYP3A4*1B is currently *CYP3A4*1.001 according to PharmGKB (pharmgkb.org).
TABLE 4 | Univariable logistic regression analysis of risk of severe ADRs according to genotypes.

|                  | Cases | Controls | OR** | 95%CI*** | p-value# |
|------------------|-------|----------|------|----------|----------|
| **Efficacy**     |       |          |      |          |          |
| Relapse          |       |          |      |          |          |
| UGT2B15          |       |          |      |          |          |
| *1/*1 (AA)       | 4     | 15       | Ref. |          |          |
| *1/*2 (AC)       | 2     | 85       | 0.088| 0.015–0.525| 0.008    |
| *2/*2 (CC)       | 3     | 40       | 0.281| 0.056–1.407| 0.123    |
| *1/*1 (AA)       | 4     | 16       | Ref. |          |          |
| *2/*2 (CC) + *1/*2 (AC) | 5 | 125     | 0.160| 0.031–0.910| 0.019    |
| *1/*1 (AA) + *1/*2 (AC) | 6 | 100     | Ref. |          |          |
| *2/*2 (CC)       | 3     | 40       | 1.305| 0.193–6.188| 0.509    |
| **Safety**       |       |          |      |          |          |
| Endometrial hyperplasia |  |          |      |          |          |
| CYP3A5           |       |          |      |          |          |
| *1/*1 (AA)       | 2     | 3        | Ref. |          |          |
| *1/*3 (AG)       | 9     | 48       | 0.281| 0.041–1.930| 0.197    |
| *3/*3 (GG)       | 4     | 89       | 0.067| 0.009–0.524| 0.010    |
| *1/*1 (AA)       | 2     | 3        | Ref. |          |          |
| *3/*3 (GG) + *1/*3 (AG) | 13 | 137     | 0.142| 0.015–1.891| 0.074    |
| *1/*1 (AA) + *1/*3 (AG) | 11 | 51       | Ref. |          |          |
| *3/*3 (GG)       | 4     | 89       | 0.208| 0.047–0.758| 0.007    |
| Vaginal bleeding |  |          |      |          |          |
| SULT1A1          |       |          |      |          |          |
| *1/*1 (GG)       | 4     | 28       | Ref. |          |          |
| *1/*2 (GA)       | 1     | 81       | 0.086| 0.009–0.806| 0.032    |
| *2/*2 (AA)       | 3     | 38       | 0.552| 0.115–2.668| 0.460    |
| *1/*1 (GG)       | 4     | 28       | Ref. |          |          |
| *2/*2 (AA) + *1/*2 (GA) | 4 | 119     | 0.235| 0.042–1.361| 0.057    |
| *1/*1 (GG) + *1/*2 (GA) | 5 | 109     | Ref. |          |          |
| *2/*2 (AA)       | 3     | 38       | 1.698| 0.254–9.300| 0.357    |
| ESRA V364E       |       |          |      |          |          |
| 364V/364V (TT)   | 3     | 96       | Ref. |          |          |
| 364V/364V (TA)   | 1     | 29       | 1.10 | 0.111–11.017| 0.933    |
| 364E/364E (AA)   | 4     | 22       | 5.81 | 1.214–27.882| 0.028    |
| 364V/364V (TT)   | 3     | 96       | Ref. |          |          |
| 364E/364E (AA) + 364V/364E (TA) | 5 | 51    | 3.137| 0.579–20.848| 0.114    |
| 364V/364V (TT) + 364V/364E (TA) | 4 | 125    | Ref. |          |          |
| 364E/364E (AA)   | 4     | 22       | 5.68 | 0.966–32.397| 0.028    |

#ADR, adverse drug reaction, evaluated with CTCAE4.03; **OR, odds ratio; ***95% CI, 95% confidence interval; #Logistic regression. Only statistically significant associations are shown (p < 0.05).

3 RESULTS

The baseline characteristics of the patients (58 ± 13 years; BMI: 29 ± 6) are shown in Table 1, and the characteristics of the patients according to genotype are shown in Supplementary Table S3. Sociogenetic gradients, risk factors, gynecological characteristics, and pathological features for descriptive analyses can also be observed. Of the total patients, 68 were premenopausal, and 94 were postmenopausal. In relation to the cancer stage at diagnosis, the majority of patients were in stage II (51.23%), the predominant histology type was invasive ductal carcinoma (86.88%), and the cell differentiation degree was predominantly G2 (54.17%). A 49.3% Ma-c was found.

Table 2 shows the therapeutic response characteristics of the patients. Relapse was found in 9 patients (5.73%). The most severely observed ADRs among patients were endometrial hyperplasia (9.20%) and vaginal bleeding (4.91%), and the most frequent were hot flashes (61.96%), bone pain (13.50%), and cramps (12.27%).

The genotypic and allelic frequencies for the analyzed polymorphisms are shown in Table 3.

We performed univariable logistic regression of the risk of relapse (Supplementary Tables S4, S5), endometrial hyperplasia (Supplementary Tables S6, S7), and vaginal bleeding (Supplementary Tables S8, S9) in association with genetic
FIGURE 1 | Research Scheme and obtained multivariate predictive models. ADRs, adverse drug reactions; BC: Breast Cancer; SULT: Sulfotransferase; UGT: UDP-glucuronosyl transferase; CYP: Cytochrome P-450; ESRA: Estrogen Receptor 1; SE: Socioeconomic status (per capita income), I: <$135,000 CLP (US$ 200); II: $135,001–$500,000 CLP (US$ 200–750); III: $500,001–$1,000,000 CLP (US$ 750–1,450); IV: >$1,000,000 CLP (US$ 1,450–2,900); HBC: Family History of Breast Cancer; HBOC: Family History of breast or ovary cancer; M: Menarche age; G: Number of Gestations; A: Number of Abortions; P: Number of deliveries; L: Breastfeeding time; Age diag: Age of diagnosis, years; OCT: Oral Contraceptive Treatment; HRT: Treatment with HRT for menopause; Menop: postmenopause; S: Cancer stage at diagnosis (Stage I-IV); DCis: Ductal carcinoma in situ; IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; OH: Others Histology (OH).
and non-genetic variables. In Table 4, only statistically significant results for the univariable logistic regression analysis (risk of relapse, endometrial hyperplasia, and vaginal bleeding) are shown. The results show that UGT2B15*2 A/C (rs1902023) in a dominant model of inheritance was associated with relapse; CYP3A5*3 A/G (rs776746) in a recessive model of inheritance was associated with endometrial hyperplasia; and SULT1A1*2 G/A (rs9282861) in a dominant model of inheritance and ESRA V364E (rs121913044) in a recessive model of inheritance were associated with vaginal bleeding.

After using stepwise forward and backward procedures, multivariate logistic regression analyses for the risk of relapse and ADRs, including genetic and non-genetic variables, were performed. We obtained significant models for endometrial hyperplasia, vaginal bleeding, phlebitis, headache, nausea, hot flush, cramps, bone pain, and urticaria (Figure 1).

Supplementary Tables S10–S12 show significant multivariate logistic regression analyses or logit models for relapse (Supplementary Table S10), endometrial hyperplasia (Supplementary Table S11) and vaginal bleeding (Supplementary Table S12) with Pseudo R² = 0.495 (p = 0.01), Pseudo R² = 0.42 (p = 0.002) and Pseudo R² = 0.34 (p = 0.014), respectively.

Associations among genetic variants with any adverse effect versus no adverse effect or with some grades of adverse effects were also assessed, but no statistical significance was observed (Supplementary Tables S13, S14).

4 DISCUSSION

Patient response to TAM has been investigated for a long time. In this respect, differences of approximately 25–50% in patients are observed (Fisher et al., 1998; Davies et al., 2011). This is an important issue due to the harmful effects on bone metabolism, cancer of the endometrium, thromboembolic diseases, and cognitive disorders caused by chronic oestrogen deprivation in cancer of the endometrium, thromboembolic diseases, and important issue due to the harmful effects on bone metabolism, increasing the sample size in future studies. Thus, in small groups, Fisher’s exact test was used to obtain proper results.

The biostatistical tools used in this field have established that non-significant trends, but with p < 0.2 and physiological significance, can be included in predictive models and in multi-variable logistic regression analysis to help predict the response (relapses) and adverse reactions to treatment (Núñez et al., 2011). Therefore, preliminary predictive models to predict the response (efficacy and safety) in TAM-treated BC patients were generated. The efficacy result, analyzed as relapse, led to a model that explains 49.5% of the possibility of presenting a relapse (p = 0.01) by including SULT1A1*2 and UGT2B15*2 and a series of relevant non-genomic variables. These results were expected since both the SULT1A1 and UGT2B15 enzymes have specificity for 4-hydroxyTAM, even though the genetic variant UGT2B15*2 presents a nucleotide change located in a substrate binding site that is associated with a decrease in catalytic activity and alterations in the Km and Vmax values (Lévesque et al., 1997). Similarly, SULT1A1*2 has a lower catalytic activity than the wild-type allele (Arslan et al., 2011). Thus, these variants would produce a decrease in the elimination of 4-hydroxyTAM.
Moreover, our results are similar to those published by Nowell and his colleagues (Nowell et al., 2002 and Nowell et al., 2005), who conducted a retrospective study in 162 TAM-treated BC patients from Arkansas who received TAM to determine whether genetic variability (CYF2D6*4, SULT1A1*2, and UGT2B15*2) in the TAM metabolic pathway was associated with recurrence. They found that high activity genotypes UGT2B15 *1/*1 and combined genotypes UGT2B15*1/*1 and SULT1A1*2/*2 lead to an increased risk of disease recurrence and that SULT1A1*2/*2 causes an approximately 3 times higher risk of death than SULT1A1*1/*1 and *1/*2. Conversely, Wegman et al. (2005) found that the genetic variants CYF2D6*4/*4, and SULT1A1*1/*1 cause an increase in the disease-free relapse time in patients with premenopausal and postmenopausal BC treated with 40 mg TAM using proportional hazards Cox regression adjusted for age, tumor size, and lymph nodes. However, Ahern et al. (2011) and Lash et al. (2011) in homologous models found that the genetic variants CYF2D6*4, UGT1A8*3, UGT2B7*2, and UGT2B15*2 did not modify the relapse rate of the disease in patients with ER+/TAM + BC. On the other hand, Sensorn et al., 2013 investigated genetic variant CYF3A4*1B (−392A>G, actually CYF3A4*1.001 G/A)*18 (877G>A), CYF3A5*3 (6986 G>A), ABCB1 3435 C>T, ABCB2*1C (−24C > T) and ABCB2 68231 A>G to evaluate the risk of recurrence within 3 years among thirty Thai women after receiving tamoxifen adjuvant therapy but they could not find CYF3A4*1B/*18, and did not observe a statistical association between CYF3A5*3, ABCB2*1C, and ABCB2 68231 A>G with clinical outcome.

Additionally, preliminary predictive models were generated to predict ADRs. The endometrial hyperplasia model explained 41.6% of the possibility of presenting the event (p = 0.002). The model includes the CYF2D6*4, CYF3A4*1B (CYF3A4*1.001), CYF3A5*3, SULT1A1*2, UGT2B15*2 and ESRA V364E genotypes plus several relevant non-genomic factors. Likewise, a preliminary predictive model was generated that explains 33.7% of the possibility of presenting vaginal bleeding (p = 0.014) by including the CYF2D6*4, CYF3A4*1B (CYF3A4*1.001), SULT1A1*2, and ESRA V364E genotypes and relevant non-genomic factors. Currently, there is no evidence regarding the association of genetic variants with TAM-induced vaginal bleeding or endometrial thickening. Chu et al. (2007) found that women with BC who carried CYF3A4*1B (CYF3A4*1.001), had a 3-fold increased risk of developing endometrial cancer after treatment with TAM. The phlebitis model explained 66% of the possibility of presenting this ADR (p = 0.036), a significant finding that has not been previously reported. In the same way, preliminary predictive models were generated to predict the appearance of headache (42.2%; p = 0.028), nausea (36.3%; p = 0.013), and hot flashes (12.1%; p = 0.023) in patients. Our results differ from those reported by Goetz et al. (2005), where CYF2D6*4/*4 tends to contribute to a higher risk of disease relapse and a lower incidence of hot flashes in a similar study. No other studies were found in the literature describing associations with headache and nausea. Finally, predictive models to predict the appearance of cramps (24.6%; p = 0.053), bone pain (14.1%; p = 0.017) and urticaria (34%; p = 0.039) were obtained. We were not able to find any similar study in the scientific literature.

Altogether, our results show that some specific genetic variants in genes encoding proteins involved in the TAM pharmacokinetic and/or pharmacodynamic can influence the efficacy of TAM therapy in BC.

Since there are still discrepancies between the findings, which may be due to the genetic differences present in the subjects analyzed, it is crucial to continue with similar and larger studies that confirm the association of CYF2D6*4, CYF2C9*2 and *3, CYF3A4*1B (CYF3A4*1.001), CYF3A5*3, SULT1A1*2, UGT2B15*2 and ESRA V364E and response to treatment with TAM. Differences in allele frequencies of variants influencing drug’s pharmacokinetics across populations are considered to result in the interethnic differences in pharmacokinetics observed. For example, the lower mean body weights of populations of East Asian in relation to European populations are well established to contribute to differences in the clearance or volume of distribution of some drugs (Lu et al., 2018). On the other hand, in relation to that scarce information is available in Latin American populations, but allele frequencies heterogeneously differ from Asian, Caucasian and African populations (Mendoza et al., 2001; López et al., 2005; Roco et al., 2012; Friedrich et al., 2014), giving rise an idea of the phenotypic response and patient outcome.

Despite our analysis, the present study has some limitations. Even though we had a good sample size for combinatorial analyses, a small number of patients examined in each subgroup comparison could mask potential associations, especially for low-frequency polymorphisms, particularly in the multivariate analyses. The small number of variants analyzed could restrict the statistical power and predictive potential of models, considering that some other candidate genes/polymorphisms were not evaluated in this study (e.g. CYF2D6 *2, *5, *6, *10 and *41, CYF2C9*2, CYF2C19 *2 and *17, UGT1A10 139Lys, UGT1A8 173Gly/277Cys and ABCC2), which could still be relevant. In some cases, missing clinical data was relevant, giving rise to a possible differential misclassification bias affecting the estimated associations between potentially relevant combinations of risk factors and adverse reactions. Other environmental factors, such as contaminants and stress, or social determinants were not explored in this study, which could potentially affect the associations.

However, our findings and preliminary predictive models proposed can be used to prevent, in a good percentage of patients, the negative effects of TAM therapy. Additionally, they could help in the decision-making of a change in therapy to aromatase inhibitors (AIs) (Bernhard et al., 2015).

Certainly, for routine clinical application, the models must be validated in terms of their specificity, sensitivity, and predictive value, so it is necessary to carry out a second stage of research that involves treatment intervention in the patient according to their genotypic profile and relevant non-genomic variables derived from this study. It should be considered that the predictive models generated in this study after being validated could be used in the Chilean population. They could be used in another...
5 CONCLUSION

In our study, UGT2B15*2 A/C is likely to have a clinically significant impact on recurrence risk, CYP3A5*3 A/G on endometrial hyperplasia, and SULT1A1*2 G/A, and ESRA V364E on vaginal bleeding in Chilean patients with breast cancer who receive tamoxifen adjuvant therapy. The obtained predictive models showed that the response to TAM treatment in BC patients is partly associated with some of the genetic variants studied. This, after a clinical validation protocol, might help to predict a percentage of disease relapse and negative effects of TAM therapy, improving the efficacy and safety of TAM pharmacotherapeutic treatment.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of the University of Chile (July 8, 2013), the Northern Metropolitan Health Service, National Cancer Institute (May 8, 2013), and Research Ethics Committee of the North Metropolitan Health Service (June 3, 2012. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

Acuña, M., Llop, E., and Rothhammer, F. (2000). Composición genética de la población chilena: las comunidades urales de los valles de Elqui, Limarí y Choapa. Rev. Méd. Chile 128 (6), 593–600. doi:10.4067/S0034-98872000000600004

Ahern, T. P., Christensen, M., Cronin-Fenton, D. P., Lunetta, K. L., Søiland, H., Gjerde, J., et al. (2011). Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors. Cancer Epidemiol. Biomarkers Prev. 20 (9), 1937–1943. doi:10.1158/1055-9965.EPI-11-0419

American Cancer Society (2017). “What Is Breast Cancer?” American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html (Accessed June 20, 2021).

Arlan, S., Silig, Y., and Pinarbasi, H. (2011). Sulfotransferase 1A1 Arg(213)His Polymorphism and Prostate Cancer Risk. Pharmacogenomics 12 (9), 1159–1162. doi:10.3892/etm.2011.334

Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C., et al. (2015). Patient-reported Outcomes with Adjuvant Exemestane versus Tamoxifen in Premenopausal Women with Early Breast Cancer Undergoing Ovarian Suppression (TEXT and SOFT): a Combined Analysis of Two Phase 3 Randomised Trials. Lancet Oncol. 16, 848–858. doi:10.1016/S1470-2045(15)00049-2

Bijl, M. J., van Schaik, R. H., Lammers, L. A., Hofman, A., Vulto, A. G., van Gelder, T., et al. (2009). The CYP2D6*4 Polymorphism Affects Breast Cancer Survival in Tamoxifen Users. Breast Cancer Res. Treat. 118 (1), 125–130. doi:10.1007/s10549-008-0272-2

Binkhorst, L., Mathijssen, R. H., Jager, A., and van Gelder, T. (2015). Individualization of Tamoxifen Therapy: Much More Than Just CYP2D6 Genotyping. Cancer Treat. Rev. 41 (3), 289–299. doi:10.1016/j.ctrv.2015.01.002

Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., et al. (2006). Quantitative Effect of CYP2D6 Genotype and Inhibitors on Tamoxifen Metabolism: Implication for Optimization of Breast Cancer Treatment. Clin. Pharmacol. Ther. 80 (1), 61–74. doi:10.1016/j.clt.2006.03.013

Brauch, H., Mürder, T. E., Eichelbaum, M., and Schwab, M. (2009). Pharmacogenomics of Tamoxifen Therapy. Clin. Chem. 55 (10), 1770–1782. doi:10.1373/clinchem.2008.121756

Brauch, H., and Schwab, M. (2014). Prediction of Tamoxifen Outcome by Genetic Variation of CYP2D6 in Post-Menopausal Women with Early Breast Cancer. Br. J. Clin. Pharmacol. 77 (4), 695–703. doi:10.1111/bcp.12229

Brewer, N. T., Defrank, J. T., Chiu, W. K., Ibrahim, J. G., Walko, C. M., Rubin, P., et al. (2014). Patients’ Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer. Public Health Genomics 17 (1), 43–47. doi:10.1159/000356565

Buckley, M. M., and Goss, K. L. (1989). Tamoxifen. A reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use. Drugs 37 (4), 451–490. doi:10.2165/00003495-198937040-00004

Carpenter, R., and Miller, W. R. (2005). Role of Aromatase Inhibitors in Breast Cancer. Br. J. Cancer 93 (Suppl. 1), S1–S5. doi:10.1038/sj.bjc.6602688

Cavalli, S. A., Hirata, M. H., and Hirata, R. D. (2001). Detection of MboII Polymorphism at the 5' Promoter Region of CYP3A4. Clin. Chem. 47 (2), 348–351. doi:10.1093/clinchem/47.2.348

Cheng, L., Swartz, M. D., Zhao, H., Kapadia, A. S., Lai, D., Rowan, P. J., et al. (2012). Hazard of Recurrence Among Women After Primary Breast cancer Treatment– a 10-Year Follow-Up Using Data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 21 (5), 800–809. doi:10.1158/1055-9965.EPI-11-1089

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.661443/full#supplementary-material

AUTHOR CONTRIBUTIONS

CM: The conception of the research, enrolment of patients, experimental analyses, analysis of data and, writing the manuscript. MG: Experimental analyses and analyses of data. RT: Enrolment of patients. KT: Enrolment of patients. DC: Analysis of data. KL: Analysis of data and writing the manuscript. MR: Analysis of data and writing the manuscript. NV: Analysis of data and writing the manuscript.

ACKNOWLEDGMENTS

The authors wish to thank the breast cancer patients from the “Instituto Nacional del Cáncer” for their altruistic collaboration in pursuit of the common welfare. We also thank the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM) by sponsoring this article.
Mendoza, R., Wan, Y. J., Poland, R. E., Smith, M., Zheng, Y., Berman, N., et al. (2001). CYP2D6 Polymorphism in a Mexican American Population. *Clin. Pharmacol. Ther.* 70 (6), 552–560. doi:10.1067/mpt.2001.120675

MINSAI (2005). *Guía Clínica Cáncer de Mama En Personas de 15 Años y Más*. 1st Ed. Santiago: Ministerio de Salud de Chile.

Mürdur, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., et al. (2011). Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. *Clin. Pharmacol. Ther.* 89 (5), 708–717. doi:10.1038/clpt.2011.27

Namipashaki, A., Razaghi-Moghadam, Z., and Ansari-Pour, N. (2015). The Essentiality of Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based Genetic Association Studies. *Cél. J.* 17, 187. doi:10.22074/celj.2016.3711

NCI (2012). Terapia Hormonal Para El Cáncer de Seno. Available at: http://www.cancer.gov/espanol/recursos/hojas-informativas/terapia/terapia-hormonal-seno (Accessed June 20, 2021).

Nishiyama, T., Oguna, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., et al. (2002). Reverse Geometrical Selectivity in Glucurononidation and Sulfation of Cis- and Trans-4-hydroxytamoxifens by Human Liver UDP-Glucuronosyltransferases and Sulfo transferases. *Biochem. Pharmacol.* 63 (10), 1817–1830. doi:10.1016/s0006-2952(02)00994-2

Nowell, S., Sweeney, A., Winters, M., Stone, A., Lang, N. P., Hutchins, L. F., et al. (2002). Association between Sulfotransferase 1A1 Genotype and Survival of Breast Cancer Patients Receiving Tamoxifen Therapy. *J. Natl. Cancer Inst.* 94 (21), 1635–1640. doi:10.1093/jnci/94.21.1635

Nowell, S. A., Ahn, J., Rae, J. M., Scheys, J. O., Trovato, A., Sweeney, C., et al. (2005). Association of Genetic Variation in Tamoxifen-Metabolizing Enzymes with Overall Survival and Recurrence of Disease in Breast Cancer Patients. *Breast Cancer Res. Treat.* 91 (3), 249–258. doi:10.1007/s10549-004-7751-x

Nüñez, E., Steyerberg, E. W., and Nüñez, J. (2011). Regression Modeling Strategies. *Rev. Esp Cardiol.* 64 (6), 501–507. doi:10.1016/j.rec.2011.01.019

Province, M. A., Goetz, M. P., Brausch, H., Fleckhart, D. A., Hebert, J. M., Whaley, R., et al. (2014). CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. *Clin. Pharmacol. Ther.* 95 (2), 216–227. doi:10.1038/clpt.2013.186

Rae, J. M., Drury, S., Hayes, D. F., Sternars, V., Thibert, J. N., Haynes, B. P., et al. (2012). CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. *J. Natl. Cancer Inst.* 104 (6), 452–460. doi:10.1093/jnci/djs126

Ramón y Cajal, T., Álés, A., Paré, L., del Río, E., Alonso, C., Barnadas, A., et al. (2010). Impact of CYP2D6 Polymorphisms in Tamoxifen Adjuvant Breast Cancer Treatment. *Breast Cancer Res. Treat.* 119 (1), 33–38. doi:10.1007/s10549-009-0328-y

Kumar, V., Abbas, A. K., and Aster, J. C. (2010). *Robbins y Cotran. Patología estructural y funcional*. 9th Ed. Barcelona: Elsevier España SA.

Roco, A., Quiriones, L., Agúndez, A. J., García-Martín, E., Squiercarini, V., Miranda, C., et al. (2012). Frequencies of 23 Functionally Significant Variant Alleles Related with Metabolism of Antineoplastic Drugs in the Chilean Population: Comparison with Caucasian and Asian Populations. *Front. Genet.* 3, 229. doi:10.3389/fgene.2012.00229

Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., et al. (2007). Breast Cancer Treatment Outcome with Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. *J. Clin. Oncol.* 25 (33), 5187–5193. doi:10.1200/JCO.2007.12.2705

Schur, B. C., Bjerke, J., Nuwayhid, N., and Wong, S. H. (2001). Genotyping of Cytochrome P450 2D6*3 and *4 Mutations Using Conventional PCR. *Clin. Chim. Acta* 308 (1–2), 25–31. doi:10.1016/s0009-8981(01)00422-3

Sensoor, I., Sirachainan, E., Charnmanphon, M., Pasomsob, E., Trachu, N., Supavilai, P., et al. (2013). Association of CYP3A4/5, ABCB1 and ABC2 Polymorphisms and Clinical Outcomes of Thai Breast Cancer Patients Treated with Tamoxifen. *Pharmacogenomics Pers Med.* 6 (1), 93–98. doi:10.2147/PGPM.S44006

Terán, J., and Teppa, A. (2005). Moduladores Selectivos de Los Receptores Estrógenicos (SERMs): Bioquímica, Farmacología y Aplicación En Ginecología. *Ginecol. Obstet. Mex* 73, 424–435.

Tucker, A. N., Tkaczuk, K. A., Lewis, L. M., Tomic, D., Lim, C. K., and Flaws, J. A. (2005). Polymorphisms in Cytochrome P450A3 (CYP3A5) May Be Associated with Race and Tumor Characteristics, but Not Metabolism and Side Effects of Tamoxifen in Breast Cancer Patients. *Cancer Lett.* 217 (1), 61–72. doi:10.1016/j.canlet.2004.08.027

Untch, M., and Thomssen, C. (2010). Clinical Practice Decisions in Endocrine Therapy. *Cancer Invest.* 28 (January), 4–13. doi:10.3109/07357907.2010.51637

Valenzuela, C., Acuña, M., and Harb, Z. (1987). Gradiente Sociogenetico En La Populación Chilena. *Rev. Med. Chil* 115, 295–299.

Varela, N., Quíones, L. A., Stojanova, J., Garay, J., Cáceres, D., Cespedes, S., et al. (2015). Characterization of the CYP2D6 Drug Metabolizing Phenotypes of the Chilean Mestizo Population through Polymorphism Analyses. *Pharmacol. Res.* 101, 124–129. doi:10.1016/j.phrs.2015.07.020

Wakeling, A. E., and Slater, S. R. (1980). Estrogen-Receptor Binding and Biologic Activity of Tamoxifen and its Metabnilites. *Cancer Treat. Rep.* 64 (6–7), 741–744.

Wegman, P., Vainikka, L., Stål, O., Nordenkäll, B., Skoog, L., Rutqvist, L. E., et al. (2005). Genotype of Metabolic Enzymes and the Benefit of Tamoxifen in Postmenopausal Breast Cancer Patients. *Breast Cancer Res.* 7 (3), R284–R290. doi:10.1186/bcr993

Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., et al. (2012). Pharmacogenomics Knowledge for Personalized Medicine. *Clin. Pharmacol. Ther.* 92 (4), 414–417. doi:10.1038/clpt.2012.96

WMA (2013). World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 310 (20), 2191–2194. doi:10.1001/jama.2013.281053

Wrenn, C. K., and Katzenellenbogen, B. S. (1993). Structure-Function Analysis of the Hormone Binding Domain of the Human Estrogen Receptor by Region-specific Mutagenesis and Phenotypic Screening in Yeast. *J. Biol. Chem.* 268 (32), 24089–24098. doi:10.1074/jbc.268.32.24089

Zhou, S. F., Di, Y. M., Chan, E., Du, Y. M., Chow, V. D., Xue, C. C., et al. (2008). Clinical Pharmacogenetics and Potential Application in Personalized Medicine. *Curr. Drug Metab.* 9 (8), 738–784. doi:10.2174/138920080786049302

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.